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ABSTRACT
Nonsteroidal antiinflammatory drugs (NSAIDs) are drugs commonly prescribed in dental practice for the management 
of pain and swelling. Of these substances, paracetamol and ibuprofen are the most widely used. Their mechanism of 
action is based on the inhibition of cyclooxygenase, and therefore of prostaglandin synthesis. All of these drugs present 
a similar mechanism of action, as a result of which their side effects are also similar. The most frequent range from 
mild (e.g., nausea or vomiting) to serious gastric problems (such as gastric bleeding or perforation). Other side effects 
include an increased risk of vascular accidents (particularly acute myocardial infarction), renal toxicity secondary to a 
decrease in perfusion, and the risk of abnormal bleeding tendency due to the antiplatelet effect of these drugs. Their use 
is contraindicated in the third trimester of pregnancy, due to the induction of premature ductus arteriosus closure. The 
present study reviews the information currently available on NSAIDs, with special emphasis on those aspects related 
to dental practice.
Key words: NSAIDs, analgesia, pain, coxibs.
RESUMEN
Los AINES son fármacos de uso común en odontología para el manejo del dolor y de la inflamación siendo paracetamol 
e ibuprofeno los más utilizados. Su mecanismo de acción está ligado a la inhibición de la ciclooxigenasa y, por tanto, de 
la síntesis de prostaglandinas. Todos poseen un mecanismo de acción similar por lo que los efectos secundarios también 
son comunes. Los más frecuentes corresponden a alteraciones gástricas leves (como náuseas o vómitos) o graves (como 
hemorragia o perforación gástrica). Otros efectos secundarios incluyen el riesgo aumentado de accidentes vasculares (en 
particular de infarto agudo de miocardio), toxicidad renal por disminución de la perfusión  y riesgo de diátesis hemorrágica 
por el efecto antiagregante plaquetario de estos fármacos. Su uso esta contraindicado en el tercer trimestre del embarazo 
por inducir el cierre prematuro del conducto arterioso. La intención del presente trabajo es revisar la información actual 
disponible sobre AINES con especial atención en aquellos aspectos relacionados con la odontoestomatología. 
Palabras clave: AINES, analgesia, dolor, coxibs
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INTRODUCTION
During the year 2004, and through the Spanish National 
Health Care System (Sistema Nacional de Salud, SNS), 
nonsteroidal antiinflammatory drugs (NSAIDs) and other 
antipyretic analgesics (paracetamol) were prescribed for a 
total of 330.33 million euros – representing 3.34% of the 
total drug prescriptions made through the SNS. Ibuprofen 
was the NSAID generating the greatest expenditure, with a 
total of 16.7 million containers, representing approximately 
100.3 million euros. In other words, ibuprofen accounted 
for a little over 30% of the total NSAID prescription costs. 
The most extensively prescribed analgesic was paracetamol, 
with 30.8 million containers, representing a total cost of 86.7 
million euros. Paracetamol moreover was the most widely 
SNS-prescribed drug substance during 2004, followed by 
omeprazole, with approximately 24.5 million containers, 
and ibuprofen in third place (1).
In the Valencian Community, and during the same time 
period, a total of 13 million NSAID and other antipyretic-
analgesic containers were prescribed.
The prescription of drugs by dentists and stomatologists 
through the SNS in the Valencian Community represented 
0.079% of the global prescriptions and 0.0417% of the total 
cost. Analgesics and antiinflammatory drugs for the same 
period and for the same health care professional sector repre-
sented approximately 20,000 prescriptions (20,302), of which 
60.88% corresponded to ibuprofen, 14.5% to pyrazolones 
(metamizol), and 10% to paracetamol. Oxicams (5%) and 
acetic acid derivatives (5%) practically accounted for the total 
of prescriptions in this therapeutic group. A significant obser-
vation is the fact that only three drugs (ibuprofen, paracetamol 
and metamizol) accounted for 85% of global analgesics-anti-
inflammatory drug prescription by dental professionals.
The NSAIDs constitute a heterogeneous group of drugs 
with analgesic, antipyretic and antiinflammatory properties 
that rank intermediately between corticoids with antiin-
flammatory properties on one hand, and major analgesics 
– opioids on the other.
Self-medication practices are very common with these drugs, 
and although they are generally quite safe, some have im-
portant side effects such as upper gastrointestinal bleeding, 
endoscopically detectable gastroduodenal ulcers, or an in-
creased risk of vascular accidents such as acute myocardial 
infarction. Patients therefore must be made aware of the 
need to use such medication by prescription only.
CLASSIFICATION
Although the NSAIDs show clear differences in biochemical 
structure and origin, they present a similar mechanism of 
action; as a result, their side effects are also similar. This 
situation is known as a “group effect”. The differences are to 
be found in the half-life of each drug, which serves to define 
the respective dosing intervals; and in the relative potency 
of each NSAID – this in turn determining the amount of 
drug substance to be administered in each dose.
Table 1 shows the NSAIDs found on the Spanish market in 
late 2005. Due to considerations of space, the associations 
of NSAIDs with other drug substances have been excluded. 
For each group of NSAIDs, the active drug substance and 
marketed pharmaceutical formulations are listed, to a maxi-
mum of four. Topical formulations have been excluded. The 
information has been obtained from the Drug Catalog of 
the year 2006, published by the Spanish General Council 
of Official Pharmaceutical Colleges (Consejo General de 
Colegios Oficiales de Farmacéuticos) (2), where the reader 
may obtain more detailed information.
Table 2 in turn reports the most commonly used NSAIDs, 
specifying the indications, forms of presentation, and the 
adult and pediatric doses.
GENERAL MECHANISM OF ACTION
NSAIDs inhibit cyclooxygenase (COX) – the enzyme res-
ponsible for the transformation of arachidonic acid into 
prostaglandins and thromboxanes, which are substances 
generically referred to as eicosanoids because their precur-
sors contain 20 carbon atoms. Arachidonic acid is funda-
mentally found in the cell membrane, where it is bound to 
phospholipids. Physical, chemical or mechanical stimuli 
(tissue damage, hypoxia, immune processes, etc.) induce 
arachidonic acid release and metabolization. The resulting 
metabolites (prostaglandins and thromboxanes) exert effects 
on practically all body organs and tissues. In relation to 
inflammation, the prostaglandins generally exert potent 
vasodilating action, resulting in increased vascular per-
meability, with the extravasation of fluids and white blood 
cells – all these phenomena contributing to inflammation. 
Consequently, the inhibition of cyclooxygenase synthesis 
exerts a clear anti-inflammatory effect.
Of particular importance in anti-inflammatory therapy was 
the identification of two different forms (isoenzymes) of 
cyclooxygenase: cyclooxygenase-1 (COX-1) and cyclooxy-
genase-2 (COX-2).
COX-1 is implicated in general homeostasis, and is found 
in most organs and tissues (constitutive isoenzyme). In 
contrast, COX-2 is not detected in tissues, and only appears 
in response to certain stimuli (inducible isoenzyme). Based 
on the hypothesis that selective COX-2 inhibition would 
induce the desired anti-inflammatory effects without the 
undesirable side effects (particularly at gastric level) asso-
ciated with COX-1 inhibition, drugs known as “coxibs” or 
selective COX-2 inhibitors have been developed.
The analgesic effect of NSAIDs results indirectly from the 
reduction of inflammation, and also directly due to action 
upon the central nervous system (CNS).
ANALGESIC POTENCY. EFFICACY
The literature abounds with publications that compare the rela-
tive efficacy of one or more NSAIDs in application to a given 
disease process – either alone or in combination with other drugs. 
There are also many articles that explore the analgesic efficacy of 
NSAIDs in the management of swelling and pain secondary to 
the removal of third molars. No classification has been establis-
hed of the analgesic-anti-inflammatory efficacy of the different 
NSAIDs equivalent to that developed for corticoids. 
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GROUP DRUG SUBSTANCE PHARMACEUTICAL PRESENTATIONS 
Butylpyrazolidines Phenylbutazone Butazolidina® 
Aceclofenac Airtal®, Falcol®, Gervin®, Sanein® 
Acemetacin Espledol®, Oldan® 
Diclofenac GDP*, Dolovoltarén®, Dolotrén®, Voltarén® …** 
Indomethacin Flogoter®, Inacid® 
Ketorolac Droal®, Toradol® 
Proglumetacin Prodanox® 
Acetic acid derivatives 
Tolmetin Artrocaptín® 
Lornoxicam Acabel®, Bosporón® 
Meloxicam GDP, Movalix®, Parocín®, Uticox®, … 
Piroxicam GDP, Feldene®, Improntal®, Vitaxicam®,… 
Oxicams 
Tenoxicam Reutenox®, Artriunic®. 
Dexibuprofen Atriscal®, Seractil®. 
Dexketoprofen Adolquir®, Enantyum®, Ketesse®, Pyrsal®, … 
Fluribuprofen Froben® 
Ibuprofen GDP, Algiasdín®, Neobrufén®, Junifen®, … 
Ketoprofen GDP, Orudis®, Fástum®, Ketosolán® 
Propionic acid derivatives 
Naproxen GDP, Nomen®, Naprosyn®, Antalgín® 
Mefenamic acid Coslán® 
Fenamates 




Pyrazolones Metamizol GDP, Nolotil®, Lasaín®, Algi-mabo®, … 
Anilides Paracetamol GDP, Gelocatil®, Termalgín®, Xumadol®, … 
Acetyl salicylic acid GDP, Aspirina®, Inyesprin®, Rhonal®, … 
Salicylic acid derivatives 
Fosfosal Aydolid®, Disdolén®, Protalgia® 
Table 1. Systemic nonsteroidal antiinflammatory drugs (NSAIDs) marketed in Spain.
* Generic drug product
**The dotted lines indicate the existence of additional drug presentations
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However, the NSAIDs exhibit a “ceiling effect” whereby 
once the recommended maximum dose has been adminis-
tered, further dose increments do not elicit an increased 
analgesic effect. Therefore, the total daily doses of  the 
different NSAIDs offer equivalent efficacy. 
In the year 2000, Gøtzsche (3) published a review on nons-
teroidal antiinflammatory drugs in which the analysis of a 
large number of meta-analyses and controlled clinical trials 
revealed no important differences in effect among the diffe-
rent NSAIDs. The study focused on rheumatoid arthrosis, 
osteoarthrosis and acute musculoskeletal symptoms. This 
author likewise found no evidence to suggest that NSAIDs 
are more effective than paracetamol in application to acute 
musculoskeletal syndromes. In this sense, Woo et al. (4) 
in 2005 published a study on the efficacy of NSAIDs and 
paracetamol in the management of pain following musculo-
skeletal limb injury, contrasting the efficacy of paracetamol, 
indomethacin, diclofenac and paracetamol plus diclofenac 
immediately after trauma and over the subsequent days. 
Although the combination paracetamol-diclofenac was 
the first to achieve significant pain relief  and induced the 
greatest reduction in pain (as evaluated by a visual analog 
scale, VAS), there were no statistically significant differences 
in mean pain reduction among the different options. The 
authors concluded that for the dosage, frequency and ad-
ministration routes used, the differences in analgesic benefit 
are small and of questionable significance.
Another hypothesis in relation to NSAIDs is the possibility 
of an increase in effect upon raising the dose. In this sense, 
and as has been commented above, it seems clear that the 
NSAIDs present a dose-response relationship that reaches 
saturation at high doses (“ceiling effect”), in the same way 
as most other drugs (3).
The preoperative administration of NSAIDs appears to be 
Drug substance Commonpresentations Dosing form Adult dose Pediatric dose 








25 mg/8 h po 





50 mg/8 h po 
















50 mg/6-12 h po 
100 mg/12-24 h im 










20 mg in starting dose + 
10 mg/4-6 h po 
10-30 mg/4-6 h im or iv 
NOT recommended 
under age 16 years 
Naproxen GDP, Naprosyn, Antalgin 550 
Tablets 
Suppositories 250-500 mg/12 h 10 mg/kg/day in 2 doses 
Piroxicam GDP, Feldene, Improntal
Tablets 
Suppositories
40 mg/day on first day 20 









500-1000 mg/6-8 h max. 6 
g/day po 
2 g/8 h iv 
1-3 years 250 mg/6-8 h 










325-650 mg/4-6 h 
1 g/8 h 
10 mg/kg every 4 h 
15 mg/kg every 6 h 
Celecoxib Celebrex Capsules 200 mg/12-24 h Not evaluated in children 
Table 2. Nonsteroidal antiinflammatory drugs (NSAIDs) commonly used in dental practice.
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more effective for the control of pain than postoperative 
administration in both oral surgery and in general surgery 
(5,6), though some authors have reported no differences 
between administration before or after surgery for certain 
NSAIDs (ketoprofen, diclofenac) (7,8). From the biologi-
cal perspective, the reduction in prostaglandin production 
would attenuate the central and peripheral nervous system 
responses to the adverse stimuli. This reduction in the 
response to pain could reduce the central and peripheral 
sensitization phenomena – and thus patient response to 
subsequent painful stimuli (9,10). However, no differences 
have been found in the concentration of PGE2 in serum 
with the pre- and postoperative administration of NSAIDs 
(ketoprofen) (11).
Although the results of the studies published in the literature 
are conflicting, it has been suggested that the pharmacological 
treatment of postoperative pain should begin before surgery 
and extend to the immediate postoperative period (12).
SIDE EFFECTS
The term “side effects” is to be preferred instead of “ad-
verse effects”, since as will be seen below, not all the effects 
described are adverse.
In general terms, the different NSAIDs have a similar me-
chanism of action – as a result of which their side effects 
are also similar.
GASTROINTESTINAL ALTERATIONS 
Gastrointestinal alterations are associated to one degree 
or other with all NSAIDs. In patients who use these drugs 
on a routine basis, nausea or dyspepsia is observed in up to 
50% of cases, with endoscopically manifest ulcerations in 
40% of patients who consume NSAIDs during a period of 
three months – though most of these lesions have no clinical 
expression. The symptoms of dyspepsia are not correlated 
to serious complications (gastrointestinal bleeding or intes-
tinal perforation) (13). The incidence of gastric or duodenal 
ulceration in chronic treatments is estimated to be 15% and 
5%, respectively (14). 
The greatest consumption of  NSAIDs corresponds to 
arthrosis-arthritis, typically in elderly patients and with 
chronic treatment regimens. In dental practice the pattern 
of use is different: with the exception of some isolated di-
sorder (e.g., chronic disorders of the temporomandibular 
joint such as osteoarthrosis), NSAIDs are prescribed for 
short periods of time in patients of all age groups, and in 
relation to acute infectious-inflammatory processes, or as 
prophylaxis against such processes. When used in this way, 
the most frequent side effects are dyspepsia, diarrhea and 
abdominal pain (15).
It is particularly important for the clinician to know which 
NSAIDs present the greatest gastrointestinal complication 
risk. In a meta-analysis conducted by Henry et al. (16) to 
evaluate the risk of serious gastrointestinal complications 
(hospital admission due to bleeding or perforation) associa-
ted with 12 commonly used NSAIDs, ibuprofen was seen to 
pose the least risk of gastrointestinal toxicity. In contrast, 
the relative risk (RR) of  some NSAIDs compared with 
ibuprofen (RR=1) reached values of up to 3.8 (piroxicam) 
and 4.2 (ketoprofen). The second least deleterious drug in 
this study was diclofenac. Indomethacin, naproxen, sulindac 
and acetylsalicylic acid (aspirin) ranked intermediate in this 
study. The use of higher ibuprofen doses is associated with 
an increase in gastrointestinal toxicity comparable to that 
of naproxen or indomethacin.
As to gastrointestinal complications according to the dura-
tion of administration, Richy et al. (17) found the maximum 
relative risk to correspond to the indole derivatives (indome-
thacin), with a value of 2.25, while the maximum frequency 
of gastrointestinal complications was recorded after 14 days 
of treatment. With other NSAIDs the relative risk was clearly 
lower (naproxen 1.83, diclofenac 1.73, piroxicam 1.66 and 
ibuprofen 1.19) – the risk being maximum after 50 days.
The risk of important gastrointestinal damage depends on 
the dose and increases dramatically when more than on 
NSAID is used (14).
The great therapeutic value of these drugs has made it ne-
cessary to develop strategies for avoiding the gastrointestinal 
risks and allow continued use. Of these strategies, two are of 
particular interest in our case: the associated administration 
of gastric mucosa protectors and development of the selec-
tive COX-2 inhibiting NSAIDs known as coxibs.
Omeprazole is a proton pump inhibitor (this pump being 
essential for acid hydrogen ion secretion into the gastric 
lumen). Its administration at a dose of 20 mg/day affords 
a 90-95% reduction in 24-hour gastric acid output. Its 
convenient dosing characteristics; scant, moderate and 
transient adverse reactions that generally do not require 
drug withdrawal; and its confirmed efficacy define ome-
prazole as the drug of choice when gastric protection must 
be associated to NSAID treatment.
Ranitidine is a specific histamine H-2 receptor antagonist. 
These receptors are located in the gastric parietal cells, and 
their blockage by ranitidine inhibits gastric secretion. The 
drug is administered at a dose of 150 mg every 12 hours, 
and usually via the oral route. It is well tolerated, and the 
adverse reactions are scarce.
Misoprostol is an analog of prostaglandin E-1 that binds 
to the specific prostaglandin receptors located in the gastric 
parietal cells, giving rise to inhibition of acid production. In 
addition, it increases the production of mucus and bicarbo-
nate. For the prevention of gastroduodenal ulcer associated 
to NSAIDs, the recommended dose is 200 µg/6-12 hours. 
The most common adverse effects are diarrhea, abdominal 
pain and vomiting.
In the review published by Gotzsche (3), misoprostol is re-
ported to reduce severe gastrointestinal complications and 
symptomatic ulcers, while the proton pump and H-2 inhibi-
tors reduce endoscopically diagnosed ulcerations – though 
the clinical relevance of these findings is uncertain.
In another study, Hippisley-Cox et al (18), investigating the 
adverse effects of NSAIDs, concluded that the administration 
of gastroprotectors reduces the risk of adverse gastrointestinal 
events in all NSAID groups except diclofenac.
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As has been commented when describing the mechanism 
of action of the coxibs (selective COX-2 inhibitors), these 
drugs appeared on the market in response to the idea that 
selective COX-2 inhibition would reduce or even eliminate 
the adverse gastric effects of the NSAIDs. The first to be 
marketed were rofecoxib (withdrawn in September 2004) 
and celecoxib. Although their principal indication was for 
chronic joint disease, the Summary of Product Characteris-
tics (SPC) of rofecoxib also specified the treatment of acute 
pain, and some studies have confirmed its therapeutic effi-
cacy in these processes (19-21)- though the recorded efficacy 
was no greater than that of the conventional NSAIDs.
It should be stressed that although these drugs are conside-
red to causes fewer gastric complications, large reviews (18) 
have been unable to draw consistent conclusions regarding 
their presumed superior gastrointestinal safety versus the 
non-selective NSAIDs. All of  them imply significantly 
increased risk, except celecoxib. On the other hand, the 
coxibs can worsen gastrointestinal inflammatory disease; as 
a result, they are contraindicated in patients with ulcerative 
colitis and in cases of Crohn’s disease. They are likewise not 
without some other adverse effects of NSAIDs such as water 
retention and kidney damage (as will be discussed below).
A dozen observational studies have been published, revea-
ling a 40-50% reduction in the risk of colon cancer among 
patients using NSAIDs. This preventive effect is believed to 
be related to the capacity of these drugs to restore apoptosis 
and inhibit angiogenesis. However, this beneficial effect is 
scantly relevant in dental practice, for although the data 
regarding the amount and duration of NSAID consumption 
are inconsistent, it seems that risk reduction increases with 
the frequency of NSAID use (22).
CARDIOVASCULAR COMPLICATIONS
Although the Summary of Product Characteristics defines 
acute myocardial infarction as a rare complication of rofe-
coxib (< 0.01%), the clinical use of the drug was associated 
with an increase in the registered number of vascular ac-
cidents – both acute myocardial infarction and stroke. As 
a result, the marketing company removed the drug from 
the market in September 2004. Authors such as Juni et 
al., in a study published in The Lancet in 2004 (23), con-
sider that the drug should have been removed long before, 
since in the year 2000 clinical trials had already identified 
relative risks of 2.30, and one year later a RR of 2.24 was 
recorded for acute myocardial infarction. The European 
Medicines Evaluation Agency (EMEA), after assessing 
the cardiovascular risks of this group of drugs (celecoxib, 
etoricoxib, valdecoxib and paracoxib), considered them to 
be contraindicated in patients with a history of ischemic 
heart disease, ischemic stroke, grade II-IV heart failure or 
peripheral arterial disease.
The Agency also recommends special caution in the use of 
these drugs when the patients present cardiovascular risk 
factors (diabetes, hypertension, hyperlipidemia, etc.) (2).
In this sense, an observational study published by Hippisley-
Cox and Coupland (24) reported a significantly increased 
risk of  acute myocardial infarction associated with the 
habitual use of rofecoxib, diclofenac and ibuprofen, with 
odds ratios (ORs) of 1.32, 1.55 and 1.24, respectively.
Posterior studies have confirmed an increased risk of 
cardiovascular events with the use of NSAIDs, and even 
with paracetamol under certain conditions. Chan et al. (25), 
in a prospective study of 71,979 women during 12 years, 
found that those who occasionally consumed NSAIDs or 
paracetamol (1-21 doses/month) were not at an increased 
risk of cardiovascular accident. Frequent consumption (> 
22 doses a month) of NSAIDs presented a relative risk of 
1.44, while frequent consumption of paracetamol implied a 
relative risk of 1.35. The use of 15 or more tablets a week bo-
osted the risk to 1.86 for NSAIDs and 1.68 for paracetamol. 
Smoking in turn substantially worsened these figures. The 
authors concluded that the habitual use of  NSAIDs or 
paracetamol implies a modest but statistically significant 
risk increase for cardiovascular events, while more moderate 
consumption poses no significant risk. Some studies have 
obtained clearly different result. Thus, in 2002, Solomon 
et al. conducted a case-control study in the United States 
(26) of  4425 patients admitted to hospital due to acute 
myocardial infarction. Risk in patients who used NSAIDs 
was seen to be the same as in those who did not. Naproxen 
was even associated with a significant reduction in the risk 
of acute myocardial infarction.
Fisher et al. (27) of Basel University, studied the risk of 
acute myocardial infarction during NSAID treatment and 
after treatment cessation. They observed a relative risk in-
crement to 1.52 in those subjects that had ceased treatment 
between 1 and 29 days previously. This risk was not observed 
in the patients who were consuming NSAIDs at the time of 
the study or in the patients who had ceased treatment 60 or 
more days previously. The conclusion of the authors was 
that the risk of acute myocardial infarction increases during 
a number of weeks after treatment discontinuation.
In conclusion, most studies reporting an increased risk of 
infarction associated with NSAIDs do so in patients who 
consume or have consumed such medication for long periods 
of  time. The studies evaluating only occasional NSAID 
consumption have revealed no rise in relative risk. Conse-
quently, the use made of these drugs in dental practice can 
be considered safe from this perspective.
ANTIPLATELET ACTION
The non-selective inhibition of cyclooxygenase induced by 
the conventional NSAIDs induces a reduction in throm-
boxane A2 synthesis, which in turn leads to the inhibition 
of platelet aggregation – an important step in hemostasia. 
This is particularly relevant in a specialty with surgical 
applications such as dental practice.
The incapacity of the platelets to produce cyclooxygenase 
explains why acetylation of this enzyme induces an irrever-
sible toxic effect that persists for the full life of the platelet 
(7-10 days) in the case of aspirin, and is reversible in the 
case of the rest of NSAIDs (14).
Braganza et al. studied gingival bleeding after administe-
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ring ibuprofen prior to periodontal surgery in 15 patients 
(28). The same patients in turn served as controls in second 
surgery in another region of the oral cavity, without prior 
ibuprofen dosing. In each case bleeding time was deter-
mined, together with the papillary bleeding index (after 
probing the papillary sulcus along the mesial and distal 
aspects, and classifying bleeding into four grades) and the 
amount of blood collected during the surgical intervention. 
The analysis of  the results showed that when ibuprofen 
was administered prior to surgery, a significant increase in 
intraoperative bleeding was observed – though in neither 
case did the blood losses have clinical relevance. A signifi-
cant increase was also seen in bleeding time. However, the 
papillary bleeding index showed no significant differences 
according to whether ibuprofen was administered or not.
When contemplating surgery, it is advisable to suppress 
NSAID medication according to the protocol recommen-
ded by the United States Food and Drug Administration 
(FDA) (15):
• 4-5 days before the intervention in the case of aspirin
• 3-4 days before in the case of NSAIDs administered once 
a day
• 2-3 days before in the case of those administered 2-3 times 
a day
• 1-2 days before in the case of those administered 4-6 times 
a day
EFFECTS ON BLOOD PRESSURE
Another adverse effect of NSAIDs is arterial hypertension 
(AHT). The consumption of  more than 500 mg/day of 
paracetamol was found to be associated with an increased 
risk of AHT (RR=1.93 in women between 51-77 years of 
age, and 1.99 in women between 34-43 years of age), while 
the consumption of  other NSAIDs was associated with 
relative risks of 1.78 and 1.60 respectively. In the mentioned 
study (29), the use of aspirin was not associated with an in-
creased risk of AHT – though earlier studies had reported a 
relationship between arterial hypertension and aspirin (30). 
The authors concluded that high doses of paracetamol and 
NSAIDs increase the risk of AHT.
As to the short-term effects of these drugs, the administra-
tion of paracetamol at a dose of 4 g/day during one month 
in hypertensive patients was seen to induce a 4 mmHg rise 
in systolic pressure (31).
In elderly patients it has been seen that those receiving treat-
ment with NSAIDs in the preceding 60 days have a risk of 
requiring the introduction of antihypertensive therapy (odds 
ratio) of 1.66 versus those who have received no such treat-
ment. Moreover, the mentioned risk was seen to increase 
with the magnitude of the administered daily dose (32).
Since the rises in blood pressure associated to NSAIDs have 
been found to accumulate in patients with treated arterial 
hypertension, with only small and nonsignificant increments 
in normotensive individuals, it has been suggested that 
NSAIDs could antagonize the effects of antihypertensive 
drugs. The results published by Johnson et al. support this 
idea (33).
KIDNEY TOXICITY
In individuals with normal kidney function, NSAID media-
ted acute renal toxicity is practically negligible. In patients 
with diminished kidney perfusion (hypotension, cirrhosis, 
congestive heart failure, diuretic use or blood loss), the ki-
dneys increase prostaglandin synthesis to raise the filtration 
rate and secure an adequate renal flow. However, inhibition 
of prostaglandin synthesis by NSAIDs can trigger renal 
hypoperfusion, nephrotic syndrome or interstitial nephritis. 
The risk is high for indomethacin and phenylbutazone, inter-
mediate for naproxen, ibuprofen, diclofenac, piroxicam and 
aspirin, and practically inexistent for paracetamol (14).
The most commonly observed side effect is peripheral edema 
secondary to inhibition of prostaglandin E2 synthesis. The 
edema and sodium retention are usually moderate, and the 
result is a 1-2 kg increase in body weight in the first weeks of 
treatment. In some rare cases the condition may be severe, 
with marked edema, important weight gain, blood pressure 
increments and heart failure (34).
Acute kidney failure with rises in blood urea, creatinine and 
potassium is a rare but serious complication. The condition 
manifests a few days after starting treatment, and appears 
faster with short half-life NSAIDs. It has occasionally been 
reported in apparently healthy individuals (35).
Attention has been drawn to the possibility of chronic in-
terstitial nephropathy and chronic renal failure associated 
with the use of NSAIDs - including paracetamol.
USE OF NSAIDS IN PREGNANCY
The ductus arteriosus diverts an important proportion of pul-
monary artery blood flow towards the descending aorta. Under 
normal conditions the duct functionally seals off immediately 
after delivery. Koren et al. (36), after reviewing the publications 
on the use of NSAIDs in the third trimester of pregnancy with 
premature closure of the ductus arteriosus, found the risk of 
such premature closure to increase as much as 15-fold in the 
offspring of women who had used indomethacin for short pe-
riods of time. The authors concluded that the use of NSAIDs in 
the final stages of pregnancy implies a significant increase in the 
risk of premature closure of the ductus arteriosus. This effect 
occurs with both selective and non-selective cyclooxygenase 
inhibitors (37), and is even observed with NSAIDs that are 
only weak prostaglandin inhibitors – such as nimesulide   – (38) 
despite the fact that premature duct closure and diminished 
kidney flow in the fetus are fundamentally considered to be 
a result of the inhibition of prostaglandin synthesis. As was 
commented at the start of this article, this cannot be regarded as 
an adverse effect in the strict sense of the word, since the same 
effect applies when administering NSAIDs as pharmacological 
treatment for persistent ductus arteriosus.
According to Ostenten et al., the classical, non-selective 
COX inhibiting NSAIDs do not increase the risk of con-
genital malformations, though they may be associated 
with infertility and miscarriage (39). These authors report 
that treatment with cyclooxygenase inhibitors should be 
suspended in week 12 of pregnancy in order to avoid the 
aforementioned problems.
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The FDA includes most NSAIDs in category B during the 
first three months of pregnancy (without evidence of tera-
togenicity in animals, or with a certain teratogenic potential 
– though without confirmation in humans). During the 
last three months of pregnancy, the NSAIDs are included 
in category D of the FDA (the studies show teratogenic 
effects, though in some cases the benefits may outweigh the 
foreseeable risks) (2).
Paracetamol is adequate during pregnancy, though it is 
advisable to prescribe the drug in consultation with an 
obstetrician.
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